Skip to content

CeriBell, Inc. CBLL Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

IAR
Integra LifeSciencesIART
-$90K+81.8%
Kestra Medical Technologies, Ltd. Common Stock logo
Kestra Medical Technologies, Ltd. Common StockKMTS
-$167K+44.7%
ICU Medical logo
ICU MedicalICUI
-$136K+92.0%
Alto Neuroscience logo
Alto NeuroscienceANRO
-$9K+78.0%

Other financials

Income statement

See full
Revenue$26.5M+29.3%
Gross profit$23.1M+28.4%
Operating income-$20.7M-46.0%
Net income-$19.7M-54.5%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$45.3M-70.5%
Total debt$22.1M+1.6%
Total equity$140.8M-22.2%
Total assets$178.1M-16.6%

Cash flow

See full
Operating cash flow-$19.3M-69.2%
CapEx$125.0K-15.5%
Free cash flow-$19.4M-68.1%

Valuation

See full
Market cap$748.61M+15.6%
Enterprise value$725.47M+40.7%
P/S7.9×-1.2×

Profitability

See full
Gross margin87.7%+0.5pp
Operating margin-68.3%+5.5pp
Net margin-63.5%+1.0pp
FCF margin-52%-1.4pp

Returns & leverage

See full
Return on equity-37.5%
Debt / equity0.2×0.0×
Current ratio10.4×-6.9×

Where this comes from

Reported directly by CeriBell, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CeriBell, Inc.'s gain/loss on asset sales?
CeriBell, Inc. (CBLL) reported gain/loss on asset sales of -$34K in Q1 2026.
How has CeriBell, Inc.'s gain/loss on asset sales changed year-over-year?
CeriBell, Inc.'s gain/loss on asset sales decreased by 25.9% year-over-year, from -$27K to -$34K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.